Cargando…
Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
Targeted therapies have produced significant treatment advances for patients diagnosed with a variety of tumor types. These therapies are associated with unique dermatologic toxicities that may hamper treatment efforts and cause significant discomfort for patients. Prevention and management of these...
Autores principales: | Eaby-Sandy, Beth, Grande, Carolyn, Viale, Pamela Hallquist |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093313/ https://www.ncbi.nlm.nih.gov/pubmed/25031940 |
Ejemplares similares
-
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
por: Lacouture, Mario E., et al.
Publicado: (2011) -
Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review
por: Leporini, Christian, et al.
Publicado: (2013) -
Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: ‘PRIDE’ Complex
por: Madke, Bhushan, et al.
Publicado: (2014) -
Management of dermatologic toxicities related to epidermal growth factor receptor inhibitor therapy across Europe: can we get a consensus?
por: Lemmens, L
Publicado: (2011) -
Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1
por: Lippolis, Catia, et al.
Publicado: (2015)